Therapeutic Uses for Blood Products and Enzyme Therapeutics
Transcript of Therapeutic Uses for Blood Products and Enzyme Therapeutics
![Page 1: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/1.jpg)
Therapeutic Uses for Blood Products and
Enzyme Therapeutics
BIT 230Walsh Chapter 9
![Page 2: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/2.jpg)
Blood and Blood Products
l Source of traditional biologicsl Blood composed of l red blood cellsl white blood cellsl plateletsl plasma (contain cellular elements) - therapeutic
proteins come from plasma
![Page 3: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/3.jpg)
Therapeutic Blood Products
l Clotting factorsl Factor VIIa VIII, IX and XIII
l Platelet concentratel Hemoglobinl whole blood (hemorrhage)l Red blood cells
![Page 4: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/4.jpg)
Risk with Blood Product Use
l Transmission of infectious diseasesl Hepatitis B and Cl HIVl Cytomegalovirus (CMV) (cold symptoms or more
serious in people with HIV)l Treponema pallidum (syphilis)l Trypanosomes
![Page 5: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/5.jpg)
Strict GMP guidelines for using blood products
l Careful screening of all donors and donationsl use of pathogen removing methods or
inactivation during processing stepsl stringent screening of all finished productsl TRACEABILITY important! - no test 100%
accurate (1/42,000 HIV negative blood unit donated is actually positive)
![Page 6: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/6.jpg)
Treatment of Blood Products
l Can’t heat inactivate or chemically treat blood product to remove pathogens
l Rely on careful screening proceduresl Chromatography steps effective in separation
of pathogens from the blood product
![Page 7: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/7.jpg)
Use of Platelets
l Key role in blood clotting processl Administered either prophylactically or
therapeutically to prevent or minimize blood loss- people suffering from thrombocytopenia (low number of thrombocytes, alternate word for platelets)
![Page 8: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/8.jpg)
Human Serum Albumin (HSA)
l Most abundant blood protein (Table 9.4 page 356 table of known plasma proteins)
l 65.5 kDa proteinl 60% of total plasma proteinl Responsible for most of blood osmotic
pressure (retaining sufficient fluid in blood vessels)
l makes blood “thicker than water”
![Page 9: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/9.jpg)
Therapeutic HSA
l Available in aqueous form or concentrated form
l plasma extender in hemorrhage, shock, burns and edema
l used after surgeryl market value about $1 billion
![Page 10: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/10.jpg)
Hemostasis
l Maintain constant blood volume; l Mechanisms for hemostasis:l congregation and clumping of platelets at site of
vascular injuryl localized constriction of blood vessel at damage
sitel induction of the blood coagulation cascade
![Page 11: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/11.jpg)
Coagulation Cascade
l Fibrinogen converts into fibrinl Fibrin aggregate at injury site, causing
thrombus (clot) formationl seals off damages area to prevent further
blood lossl Process: 12+ blood clotting factors involved
in cascade
![Page 12: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/12.jpg)
Coagulation CascadeCoagulation pathway
![Page 13: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/13.jpg)
Factor Name
I Fibrinogen
II Prothrombin
III Tissue factor or thromboplastin
IV Calcium ions
V Proaccelerin (Labile factor)
VII Proconvertin (Stable factor)
VIII Antihemophilic factor A, Antihemophilic globulin
IX Antihemophilic factor B, Plasma thromboplastin component, Christmas factor
X Stuart-Prower factor
XI Plasma thromboplastin antecedent, Hemophilia C, Rosenthal syndrome
XII Hageman factor
XIII Fibrin stabilizing factor, Laki-Lorand factor
Coagulation Factors
![Page 14: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/14.jpg)
Coagulation Factors cont’d
l Roman numeral designation (see factors in Table 9.5 page 359 and next slide)
l Intrinsic and extrinsic pathwaysl Intrinsic - cascade that utilizes only factors
that are soluble in the plasmal Extrinsic - some factors that are insoluble in
the plasma, e.g., membrane-bound factors (factor VII)
![Page 15: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/15.jpg)
coagulation lecture
See this PowerPoint Presentation
![Page 16: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/16.jpg)
RJ GilliesBC801
Overview of blood coagulation
VesselInjury
PlateletActivation
TissueFactor
CoagulationCascade
PlateletAggregation
PlateletPlug
Thrombin
Clot
Vasocon-striction
Adhesion to vWF
Release of ProstaglandinsRelease of ATP, factor V, fibrinogen, HMWK , Ca2+
www.biochem.arizona.edu
![Page 17: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/17.jpg)
Genetic disorders
l Lack of gene expression of clotting factorl altered amino acid sequence of clotting factorl both intrinsic and extrinsic pathways must
work for proper clottingl results of mutations bruising or prolonged
bleeding
![Page 18: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/18.jpg)
Disorders cont’d
l 90% of characterized disorders deficiency in factor VIII, rest due to factor IX
l treatment administration of whole blood or relevant coagulation factor (purified from whole blood)
l recombinant factors important to minimize risk of exposure to blood pathogens
![Page 19: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/19.jpg)
Factor VIII - Hemophilia
l Hemophilia Al X-linked recessive diseasel Intact VIII- made up of 2 products, factor VIII
and von Willebrand factor (vWF)l 1-2 million Dal fully intact VIII needed to enhance activation
rate of factor IX of intrinsic system
![Page 20: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/20.jpg)
Hemophilia
l Level of intact factor VIII affects severity of disease (need at least 5% expression)
l rarer von Willibrand’s disease- lack both components of factor VIII complex
l Administer weekly factor VIII complex for life
![Page 21: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/21.jpg)
rVIII
l Expressed VII:C cDNA in CHO and BHK cellsl clinical studies show equivalent effects of
recombinant and native isolated factor VIIIl some problems due to immunogenic
responsel same production issues as with any biologic
![Page 22: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/22.jpg)
Factor IX
l Hemophilia Bl rarer diseasel treatment is administration of concentrated
factor IXl produced recombinantly in CHO cellsl also X-linked recessive
![Page 23: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/23.jpg)
Anticoagulants
l Inappropriate clotting dangerousl Occurs in blood vessels, impedes blood flowl results in heart attack (coronary thrombosis
resulting in m.i.) or stroke (blood vessel that supplies the brain)
![Page 24: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/24.jpg)
Major Anticoagulants
l Heparinl Warfarinl Hirudinl Ancrodl Protein Cl Dicoumerol
![Page 25: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/25.jpg)
Heparin
l Proteoglycan - make up of large carbohydrate component, so more like a poly-sugar than a protein
l injected drugl found in mast cells in endothelium of blood vesselsl activates antithrombin (plasma protein)- inactivates
clotting factorl One of few carbohydrate product with therapeutic
application
![Page 26: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/26.jpg)
Vitamin K Antimetabolites
l Dicoumarol and warfarin- given orallyl prevent vitamin K-dependent carboxylation of
factors II, VII, IX and Xl hinders effective functioning of the coag
cascadel Side effect: prolonged bleedingl need to choose dosage carefully
![Page 27: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/27.jpg)
Hirudin
l Directly inhibits thrombin by binding to itl isolated from leech saliva in Hirudo medicinalisl short 65 aa polypeptidel does not require a co-factorl weak immunogenl not as much bleeding side effectsl Trade name: Refludan (purifying scheme in Figure
9.15, page 378)
![Page 28: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/28.jpg)
Thrombolytic Agents
l Thrombosis function to plug damaged blood vessel
l after repair, blood clot is removed via enzyme degradation (fibrinolysis)
l when inappropriate clot forms, damage minimized if you can speed up removal of clot
l Agents developed to do so
![Page 29: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/29.jpg)
Thrombolytic Agents
l tPAs (see diagram of action Figure 9.18 Page 382)l Activase (Genetech)l Ecokinase (Galenus Mannheim)l Retavase (Boehringer-Mannheim/Centocor)l Rapilsyn (BM)
l TNKasel Streptokinasel Urokinase
![Page 30: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/30.jpg)
Tissue plasminogen activator
l Plasmin catalyzes degradation of fibrin in clots (dissolving clot)
l plasmin derived from plasminogenl plasminogen synthesized and released from
kidneys; 90 kDa proteinl tPA potently activates plasminogen
![Page 31: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/31.jpg)
Early tPA
l Studied in 40’s; normal low level made it difficult to characterize
l Bowes melanoma cell line secretes large amounts of tPA
l cloned in “83 and produced in CHO cellsl Genentech got first tPA license in 1987
(Activase)l need to treat within hours of m.i.
![Page 32: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/32.jpg)
Recombinant tPA
l Several modified forms to improve efficacy (faster- acting, prolonged half-life)
l produced in E. coli (Ekokinase, Retavase and Rapilysin)
l no glycosylation leads to prolonged serum half-life
![Page 33: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/33.jpg)
Enzymes as Therapies
l Table 9.12, page 389l Enzymes given intravenouslyl encapsulate or covalently modify enzymes to
counteract antigenicity or short half-livesl capsule needs to be non-immunogenic
materiall Liposomes- facilitate entry into cell (used in
transfection protocols)
![Page 34: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/34.jpg)
Glucocerebrosidase
l Used to treat Gaucher’s diseasel disease affects lipid metabolism - these are
lipids such as sphingosine, found in brain and neural tissue, associated with myelin sheath of nerves
l symptoms- enlargement of liver and spleen, mental retardation
![Page 35: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/35.jpg)
Glucocerebrosidase cont’d
l Genzyme Corp. in Boston- marked in 1991-brand name Ceredase -taken from placenta
l administration to Gaucher’s patients relieve symptoms of disease
l Cerezyme- recombinant version produced in CHO cells
l $200 million market
![Page 36: Therapeutic Uses for Blood Products and Enzyme Therapeutics](https://reader031.fdocuments.us/reader031/viewer/2022020703/61fb2a502e268c58cd5aec83/html5/thumbnails/36.jpg)
Digestive aids
l Used in compromised digestive functions, such as cystic fibrosis
l another e.g. - lactase, aids in lactose intolerance
l pepsin- degradation of dietary proteinl pancreatin - degradation of dietary
carbohydrate, fat and protein